Levels of homotypic and heterotypic dengue virus (DENV) neutralizing antibodies (Abs) induced by chimeric yellow fever–dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in preimmune subjects. A, Proportions of DENV homotypic neutralizing antibodies induced by vaccine. The antibody depletion assay was used to measure proportions of DENV type-specific (homotypic) neutralizing antibodies induced by CYD-TDV in DENV-preimmune subjects. Each data point represents the percentage of the total neutralizing antibody response to a serotype attributed to type-specific antibodies; horizontal bars represent geometric mean titers. B–D, Absolute levels of type-specific DENV neutralizing antibodies before and after vaccination with CYD-TDV. The antibody depletion assay was used to measure absolute levels of DENV type-specific (homotypic) and cross-reactive (heterotypic) neutralizing antibodies induced by CYD-TDV. Homotypic antibody is shown in solid black; heterotypic antibody, in stripes. Bars represents the total 50% neutralization antibody titer (Neut50) for each serotype. Neutralizing antibody levels in subjects with evidence of prevaccination DENV2 exposure (B), DENV3 exposure (C, left to right), and secondary exposure (D, left to right) are depicted as separate graphs.